10 / 24
First-Line Treatment of mPCA:
nab
-Paclitaxel + Gemcitabine or FOLFIRINOX?
nab
-P/Gem (n = 431)
FOLFIRINOX (n = 171)
Sites
Global
France
Age >75?
Yes
?
PS
0-2
0-1
Efficacy
RR,%
PFS, months
OS (updated), months
1 year, %
29
5.5
8.7
35
31.6
6.4
11.1
48
Safety, G ≥3 events, %
Febrile neutropenia
Growth factors
Fatigue
Vomiting
Diarrhea
Neuropathy
3
26
17
3
6
17
5
43
24
15
13
9
Von Hoff DD, et al.
N Engl J Med
. 2013;369(18):1691-1703. Goldstein D, et al.
J Natl Cancer Inst.
2015;107(2):dju413. Conroy T, et al.
N Engl J Med.
2011;364(19):1817-1825.
G, grade; PS, performance status; mPCA, metastatic pancreatic cancer
FFX popula)on
Younger
Less sick-healthier
Less cancer burden
More 2
nd
line therapy